Bonjesta 20 mg / 20 mg, Tablette mit veränderter Wirkstofffreisetzung

7680688670042 CH-68867 Tablette

Associated product:

BONJESTA cpr ret 20mg/20mg 40 pce

No image available

Article details

Package size
40
Selling units
40
Measure
Tablette(n)
Galenic form
Tablette
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
03/07/2026
Patient information leaflet
Français
03/07/2026
Patient information leaflet
Italien
03/07/2026
Summary of Product Characteristics
Allemand
03/07/2026
Summary of Product Characteristics
Français
03/07/2026
Summary of Product Characteristics
Italien
03/07/2026

Detailed composition

Substance Quantity Type Category
doxylamini hydrogenosuccinas
20.0 MG Substance Wirkstoff (Principe actif)
pyridoxini hydrochloridum
20.0 MG Substance Wirkstoff (Principe actif)
cellulosum microcristallinum
- Substance HNIDK
magnesii trisilicas hydricus
- Substance HNIDK
carmellosum natricum conexum
- Substance HNIDK
magnesii stearas
- Substance HNIDK
silica colloidalis anhydrica
- Substance HNIDK
hypromellosum
- Substance HNIDK
triethylis citras
- Substance HNIDK
simeticoni emulsio
- Substance HNIDK
dimeticonum
- Substance HNIDK
polysorbatum 65
- Substance HNIDK
silica colloidalis
- Substance HNIDK
methylcellulosum
- Substance HNIDK
poly(dimethylsiloxani) elastomerum
- Substance HNIDK
mono/diglycerida
- Substance HNIDK
acidum sulfuricum
- Substance HNIDK
E 200
- Substance Konservierungsstoff (Conservateur)
E 210
0.007 UG Substance HBESI
acidi methacrylici et ethylis acrylatis polymerisatum 1:1
- Substance HNIDK
talcum
- Substance HNIDK
silica colloidalis anhydrica
- Substance HNIDK
natrii hydrogenocarbonas
- Substance HNIDK
natrii laurilsulfas
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
poly(alcohol vinylicus)
- Substance HNIDK
titanii dioxidum
- Substance HNIDK
macrogolum 3350
- Substance HNIDK
E 172 (rubrum)
- Substance FTODK
E 172 (nigrum)
- Substance FTODK
cera carnauba
- Substance HNIDK
lacca
- Substance HNIDK
E 129
- Substance HBESI
propylenglycolum
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
E 132
- Substance FIMDK
ammoniae solutio 28 per centum
- Substance HNIDK
simeticonum
- Substance HNIDK
natrium
0.38 MG Substance HBESI

Reimbursement information

Public price
CHF 70.60
Specialties list
Yes
Generic
No
SL addition date: 01/05/2026

Authorization holder

Exeltis Suisse SA

1228 Plan-Ies-Ouates

Authorization information

Swissmedic authorization number
68867
Drug name
Bonjesta, Tablette mit veränderter Wirkstofffreisetzung
Galenic form
TABWF
ATC Code
R06AA59
Authorization status
Z
Dispensing category
B
First authorization
05/12/2023
Authorization expiration date
04/12/2028
IT Number
01.09.0.
Domain
Human medicine
Field of application
symptomatischen Behandlung von Übelkeit und Erbrechen während der Schwangerschaft bei Frauen, die nicht auf eine konservative Behandlung ansprechen

Package details

Description (FR)
BONJESTA cpr ret 20mg/20mg 40 pce
Description (DE)
BONJESTA Ret Tabl 20mg/20mg 40 Stk
Market launch
01/04/2026
Narcotic (BTM)
No

Other package sizes (5)

None
10 TABL
GTIN: None
Not in V1
BONJESTA cpr ret 20mg/20mg 20 pce
20 TABL
GTIN: 7680688670028
View
None
30 TABL
GTIN: None
Not in V1
None
50 TABL
GTIN: None
Not in V1
None
60 TABL
GTIN: None
Not in V1
Buy us a coffee Explore the data